{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:39:19Z","timestamp":1783708759618,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brazilian Journal of Otorhinolaryngology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.bjorl.2020.09.010","type":"journal-article","created":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T16:44:08Z","timestamp":1603644248000},"page":"683-690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9992-3451","authenticated-orcid":false,"given":"Aristilia Pricila Tahara","family":"Kemp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8385-6549","authenticated-orcid":false,"given":"Vitor Hugo Candido","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8603-2614","authenticated-orcid":false,"given":"Rafael Zancan","family":"Mobile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-3138","authenticated-orcid":false,"given":"Thais Bianca","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-2498","authenticated-orcid":false,"given":"Laurindo Moacir","family":"Sassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9329-0374","authenticated-orcid":false,"given":"Amanda","family":"Zarpellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1842-9521","authenticated-orcid":false,"given":"Paulo Henrique","family":"Braz-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5204-0782","authenticated-orcid":false,"given":"Juliana Lucena","family":"Schussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjorl.2020.09.010_bib0005","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","article-title":"Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates","volume":"68","author":"Lazarovici","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jcms.2011.05.003","article-title":"Bisphosphonate-related osteonecrosis of the jaws \u2014 characteristics, risk factors, clinical features, localization and impact on oncological treatment","volume":"40","author":"Otto","year":"2012","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0015","first-page":"2477","article-title":"Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates","volume":"34","author":"Iulliis","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0020","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw \u2014 2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ctrv.2015.04.007","article-title":"Drug induced osteonecrosis of the jaw","volume":"41","author":"Hamadeh","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0030","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0022034515572021","article-title":"Infection and medication-related osteonecrosis of the jaw","volume":"94","author":"Katsarelis","year":"2015","journal-title":"J Dent Res"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0035","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?","volume":"45","author":"Lesclous","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0040","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0045","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","article-title":"A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates","volume":"35","author":"Thumbigere-Math","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0055","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5125\/jkaoms.2019.45.2.108","article-title":"Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation","volume":"45","author":"Sahin","year":"2019","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0060","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025600","article-title":"Database analysis of the risk factors of bisphosphonate-related osteonecrosis of the jaw in Hungarian patients","volume":"9","author":"Veszelyne Kotan","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-018-4746-8","article-title":"Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study","volume":"30","author":"Hasegawa","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0075","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.eururo.2008.06.070","article-title":"Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate","volume":"54","author":"Walter","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0080","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0085","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.4317\/medoral.18604","article-title":"Intravenous bisphosphonate-related osteonecrosis of the jaws: influence of coadjuvant antineoplastic treatment and study of buccodental condition","volume":"18","author":"Margaix-Munoz","year":"2013","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0090","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0095","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","article-title":"Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study","volume":"66","author":"Wessel","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/odi.12150","article-title":"Interleukin-6 concentration changes in plasma and saliva in bisphosphonate-related osteonecrosis of the jaws","volume":"20","author":"Bagan","year":"2014","journal-title":"Oral Dis"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jop.12021","article-title":"Bisphosphonates-related osteonecrosis of the jaws: a preliminary study of salivary interleukins","volume":"42","author":"Bagan","year":"2013","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0110","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/clpt.2009.313","article-title":"Interleukin-6 as a therapeutic target in candidate inflammatory diseases","volume":"87","author":"Nishimoto","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1749-6632.1993.tb18343.x","article-title":"Methods for collecting saliva","volume":"694","author":"Navazesh","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0125","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Corso","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0130","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0135","doi-asserted-by":"crossref","first-page":"e948","DOI":"10.4317\/medoral.17946","article-title":"Bone metabolism and clinical study of 44 patients with bisphosphonate-related osteonecrosis of the jaws","volume":"17","author":"Bocanegra-Perez","year":"2012","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0140","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00784-012-0800-7","article-title":"Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid","volume":"17","author":"Mozzati","year":"2013","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00590-014-1488-y","article-title":"Smoking cessation and bone healing: optimal cessation timing","volume":"25","author":"Truntzer","year":"2015","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0765.2010.01306.x","article-title":"Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6","volume":"46","author":"Tipton","year":"2011","journal-title":"J Periodontal Res"},{"key":"10.1016\/j.bjorl.2020.09.010_bib0165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ijos.2014.46","article-title":"Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw","volume":"6","author":"Pushalkar","year":"2014","journal-title":"Int J Oral Sci"}],"container-title":["Brazilian Journal of Otorhinolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1808869420301762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1808869420301762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:38:07Z","timestamp":1761723487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1808869420301762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1808869420301762"],"URL":"https:\/\/doi.org\/10.1016\/j.bjorl.2020.09.010","relation":{},"ISSN":["1808-8694"],"issn-type":[{"value":"1808-8694","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients","name":"articletitle","label":"Article Title"},{"value":"Brazilian Journal of Otorhinolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjorl.2020.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Associa\u00e7\u00e3o Brasileira de Otorrinolaringologia e Cirurgia C\u00e9rvico-Facial. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}